Plus Therapeutics Inc (PSTV NASDAQ) stock market data APIs
$0.6195
0(0%)
as of October 24, 2025
Try our APIs with
free plan!
Plus Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Prev. Close
0.6195
Open
0.6195
High
0.6309
Low
0.5965
52 wk Range
0.16-2.31
Market Cap
63 013 K
Shares Outstanding
99 265 K
Revenue
5 317 K
EPS
-0.0065
Beta
0.81
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Plus Therapeutics Inc data using free add-ons & libraries
Get Plus Therapeutics Inc Fundamental Data
Plus Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 317 K
- EBITDA: -12 152 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Plus Therapeutics Inc News
New
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Plus Therape...
Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics
For Immediate Release Chicago, IL – October 15, 2025 – Today, Zacks Equity Research discusses Akebia Therapeutics AKBA, Ironwood Pharmaceuticals IRWD, Pyxis Oncology PYXS, Cardiol Therapeutics CR...
5 Small Drug Stocks to Buy as the Industry Shows Some Recovery
The drug and biotech sector bounced back this month after struggling this year due to tariff and pricing fears and broader macro headwinds. The recovery was propelled by Pfizer’s landmark drug-prici...
Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare
We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday. Shares of Plus Therapeutics soared by 39.2...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
